sec filing - novogen yale uni joint venture , page-23

"Would the market reaction be as a result of the 85% stake that novogen has received via the partnership. Maybe many investments would view that as a dilution of 15%."

safiya,it was "NOT" a 85%/15% split of Novogen to Yale, it was just for one drug pipeline Triaxial only and it was
"NOT" for the IP either, it was just for that particular drugs development, I am assuming that Yale will front up for the trial costs, so I see it as a positive.

Novogen will still hold all of the IP they have, they will also have many new drugs in their own NRT stable as well as the one they just purchased and they will also hold the manufacturing IP they have discovered which will also apply to the making of many drugs, not just cancer drugs.